Brind.

Krystal Biotech maintained nationwide access in the US and received VYJUVEK approval in Japan for DEB treatment.

4 reports, 1 independent Updated Aug 4
Gone quiet
Reports
4
Developments
3
Repetition
25%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Krystal Biotech maintained nationwide access in the US and received VYJUVEK approval in Japan for DEB treatment.

Who's involved

What this event is mainly about
Krystal Biotech, Inc.

How it developed

Newest first. Tap a step to see who reported it.
  1. VYJUVEK received approval in Japan, and the company maintained strong US nationwide access.1 source
  2. Krystal Biotech's VYJUVEK received approval in Europe.1 source
  3. DEB affected patient count in the US exceeds 750.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireKrystal Biotech Announces Second Quarter 2025 Financial and Operating Results $96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatmen
  • GlobeNewswireKrystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stag
  • GlobeNewswireKrystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa VYJUVEK approved for the treatment of DEB from b
  • Unknown outlet